Business
President Donald Trump impeached
(Robert Alexander/Getty Images)
Broad-sheeeeeeeettt

The New York Times didn’t get as much of a “Trump bump” as investors wanted

Last time around, newspapers got a big boost from nonstop Trump coverage.

On Wednesday, The New York Times Company reported that it had gained another 350,000 digital-only subscribers in the last quarter. That pushed the NYT’s total subscriber count to more than 11.4 million, maintaining its crown as the world’s largest news company to have successfully pivoted away from its print media roots. Indeed, just 21% of the company’s revenue came from print subscriptions last year, half the proportion from just a decade ago, as the newspaper’s push into games, cooking, and product recommendations has broadened its appeal. As one Sherwood writer summarized last year: “The New York Times is a games company with a newspaper side hustle.” The company also hiked its dividend by 38%.

(Hard) Times

On the surface, that sounds... good? Except that investors in The New York Times have become accustomed to quarter after quarter of strong digital growth and the company’s guidance for the coming year left traders unimpressed, with NYT shares falling a whopping 12% in Wednesday trading as investors digested the disappointing forecasts.

NYTimes Revenue
Sherwood News

Of particular note was that the Q4 “Trump bump” didn’t materialize as much as NYT execs might have hoped.

In 2016, following Donald Trump’s remarkable ascension to the White House, the news media industry enjoyed bumper traffic and heightened interest in politics as President Trump enacted his MAGA agenda. Many expected that phenomenon to happen again. And, in terms of pure traffic, it briefly did: data from Similarweb reveals a sharp spikes in daily visitors to some of the nation’s most popular news sites around the election.

Trump bump
Sherwood News

So far, however, the election has yet to translate into a sustained news media boom. Editors and execs have only enjoyed a truncated “Trump bump,” as it were.

In defense of The New York Times, the company itself ran an article on the subject in the wake of the election, pouring some cold water on the expectation that Trump 2024 would be like Trump 2016: “News fatigue and changing consumption habits could sap some of that enthusiasm over time, several news media experts said.”

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26
2025 WWD Beauty CEO Summit - Day 2

CFO Mandy Fields sees e.l.f. Beauty in growth mode, as company beats on sales and earnings

The new owner of rhode beat estimates for its fiscal third quarter and boosted its guidance for the full year, even as headwinds in the UK and Germany continued.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.